Filtered By:
Drug: Rituxan
This page shows you your search results in order of relevance. This is page number 19.
Order by Relevance | Date
Total 7090 results found since Jan 2013.
A study of 65 patients with acquired hemophilia A in Taiwan
Conclusion The salient features of AHA and treatment outcomes of the patients in this study are similar to those of other patients. Two independent factors (the use of a Rb regimen and platelet < 1.5 × 1011/L) were significantly associated with TRS.
Source: Journal of the Formosan Medical Association - April 2, 2015 Category: Journals (General) Source Type: research
B cells and immunoglobulin in ABO-incompatible renal transplant patients receiving rituximab and double filtration plasmapheresis
Conclusion With the aid of tacrolimus and mycophenolate mofetil, rituximab resulted in sustained suppression of B cell count and total IgG and IgM. Among the IgG subclasses, IgG3 was less sensitive to rituximab.
Source: Journal of the Formosan Medical Association - April 2, 2015 Category: Journals (General) Source Type: research
Rituximab in Thrombotic Thrombocytopenic Purpura: Medical and Financial Benefits.
PMID: 25997593 [PubMed - as supplied by publisher]
Source: Acta Haematologica - May 20, 2015 Category: Hematology Authors: Scully M Tags: Acta Haematol Source Type: research
Kidney transplantation in highly sensitized patients
Background
Desensitization, a term loosely referring to a collection of antibody reduction and B-cell depletional therapies aimed at improving rates of transplantation in highly HLA and ABO-incompatible transplant recipients, has seen significant growth in the last decade. Advancements relate to an increasing unmet medical need for FDA-approved therapies, advancements in antibody detection methodologies and improved renal pathological assessments of antibody-mediated rejection (ABMR).
Sources of data, areas of agreement and controversy
Data reviewed include collective summaries of experience with high-dose intravenous imm...
Source: British Medical Bulletin - June 1, 2015 Category: Journals (General) Authors: Jordan, S. C., Choi, J., Vo, A. Tags: Transplantation Articles Source Type: research
The impact of a computerized physician order entry system on medical errors with antineoplastic drugs 5 years after its implementation
The objectives of this study were to determine the impact of a CPOE on the number of MEs and to identify the types of MEs in prescriptions issued by the Haematology Department 5 years after the implementation of the CPOE system.
MethodsWe conducted a prospective analytical study on the implementation of a CPOE system at the Pharmacy Department of the Hospital Ramon y Cajal (Madrid, Spain). The study comprised three phases: a pre‐implementation phase, an implementation phase conducted in the Haematology Department and a post‐implementation phase, which was conducted 5 years after the implementation of the CPOE system....
Source: Journal of Clinical Pharmacy and Therapeutics - July 14, 2015 Category: Drugs & Pharmacology Authors: M. Sanchez Cuervo, A. Rojo Sanchis, C. Pueyo Lopez, E. Gomez de Salazar Lopez de Silanes, T. Gramage Caro, T. Bermejo Vicedo Tags: Original Article Source Type: research
Rituximab Safe for Up to 11 Years in Rheumatoid Arthritis Rituximab Safe for Up to 11 Years in Rheumatoid Arthritis
An analysis of data for nearly 3000 patients with RA treated with rituximab for up to 11 years showed no increased risk for serious infection cardiac events or malignancy. Medscape Medical News
Source: Medscape Medical News Headlines - September 1, 2015 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Medical Treatment of Graves’ Orbitopathy
Horm Metab Res 2015; 47: 779-788DOI: 10.1055/s-0035-1554721The medical treatment of Graves’ orbitopathy (GO) is usually reserved to moderate to severe disease. Steroids have been widely employed and possess anti-inflammatory activity, but about 20–30% of patients are not responsive and about 20% present with disease recurrence. Immunosuppressive therapy alternative to corticosteroids may target the different antigens involved in pathogenic mechanisms of GO. Some have already been employed in clinical studies and showed interesting results, although the lack of randomized and controlled trials suggests caution for their...
Source: Hormone and Metabolic Research - September 11, 2015 Category: Endocrinology Authors: Salvi, M.Campi, I. Tags: Review Source Type: research
Rituximab Emerging as New Option for Membranous NephropathyRituximab Emerging as New Option for Membranous Nephropathy
The treatment of membranous nephropathy remains controversial, but new data suggest that adding rituximab to nonimmunosuppresive antiproteinuric therapy is an option. Medscape Medical News
Source: Medscape Medical News Headlines - November 16, 2015 Category: Consumer Health News Tags: Nephrology News Source Type: news
Idelalisib Trial Stopped Because of 'Overwhelming Efficacy'Idelalisib Trial Stopped Because of 'Overwhelming Efficacy'
In chronic lymphocytic leukemia, idelalisib combined with bendamustine and rituximab improved progression-free and overall survival compared with the standard two-drug combination. Medscape Medical News
Source: Medscape Medical News Headlines - December 9, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
The Effects of Rituximab on Lipids, Arterial Stiffness and Carotid Intima-Media Thickness in Rheumatoid Arthritis.
Authors: Novikova DS, Popkova TV, Lukina GV, Luchikhina EL, Karateev DE, Volkov AV, Novikov AA, Aleksandrova EN, Nasonov EL
Abstract
The aim of the study was to examine lipid profiles, arterial stiffness (AS), carotid intima-media thickness (cIMT), in 55 women with RA without overt cardiovascular disease (СVD) treated with rituximab (RTX).The following parameters were recorded before and 24 weeks after RTX therapy (2 infusions of 500 or 1,000 mg RTX intravenously, fortnightly): plasma total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides, D...
Source: Journal of Korean Medical Science - February 4, 2016 Category: Biomedical Science Tags: J Korean Med Sci Source Type: research
Post-transplant lymphoproliferative disorder in paediatric patients: the Irish perspective—a single centre experience
Conclusion
The outcome of paediatric patients treated for PTLD at our institution is at least comparable to published international series and supports the use of rituximab ± low dose chemotherapy in the treatment of this malignancy.
Source: Irish Journal of Medical Science - February 29, 2016 Category: Journals (General) Source Type: research
Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data
Conclusions: These analyses, based on real-world evidence, show that the introduction of rituximab into clinical practice has produced a substantial number of incremental life-years. Importantly, the economic benefit of the life-years gained greatly exceeds the added costs of treatment.
Source: Medical Care - March 17, 2016 Category: Health Management Tags: Original Articles Source Type: research
Obinutuzumab Similar to Rituximab in DLBCLObinutuzumab Similar to Rituximab in DLBCL
A clinical trial comparing the two products in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) failed to meet its endpoint, the company announced. Medscape Medical News
Source: Medscape Medical News Headlines - July 18, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Immune-Modulating Agents Eyed for ' Chronic Fatigue Syndrome ' Immune-Modulating Agents Eyed for ' Chronic Fatigue Syndrome '
Two Norwegian oncologists are investigating the use of rituximab and other immune-modulating agents to treat the controversial condition, while also delving into its energy-depleting cause.Medscape Medical News
Source: Medscape Medical News Headlines - November 11, 2016 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Rituximab Maintenance Ups Survival in MCL After Transplant Rituximab Maintenance Ups Survival in MCL After Transplant
Younger patients with mantle cell lymphoma who have undergone transplant should be given rituximab maintenance, the LyMa trial concludes.Medscape Medical News
Source: Medscape Medical News Headlines - December 4, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
